William J. Muller

William J. Muller

Auto-generated profile, based on publicly available information

William J. Muller

Division of Infectious Diseases Ann & Robert H. Lurie Children's Hospital of Chicago Chicago Illinois USA

Research Focus & Metrics

Academic Career Length

38Years (1989-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 March 2022 in New England Journal of Medicine
Verified
Journal Article
Closed access
PDF file
LHLaura L. Hammitt
Laura L. Hammitt
RDRon Dagan
Ron Dagan
YYYuan Yuan
Yuan Yuan
MCManuel Baca Cots
Manuel Baca Cots
MBMiroslava Bosheva
Miroslava Bosheva
TVTonya Villafana
Tonya Villafana
Respiratory syncytial virus (RSV) is a major cause of lower respiratory tract infection and hospitalization in infants. Nirsevimab is a monoclonal antibody to the RSV fusion protein that has an extended half-life. The efficacy and safety of nirsevimab in healthy late-preterm and term infants are uncertain. We randomly assigned, in a 2:1 ratio, infants who had been born at a gestational age of at least 35 weeks to receive a single intramuscular injection of nirsevimab or placebo before the start of an RSV season. The primary efficacy end point was medically attended RSV-associated lower respiratory tract infection through 150 days after the injection. The secondary efficacy end point was hospitalization for RSV-associated lower respiratory tract infection through 150 days after the injection. A total of 1490 infants underwent randomization: 994 were assigned to the nirsevimab group and 496 to the placebo group. Medically attended RSV-associated lower respiratory tract infection occurred in 12 infants (1.2%) in the nirsevimab group and in 25 infants (5.0%) in the placebo group; these findings correspond to an efficacy of 74.5% (95% confidence interval [CI], 49.6 to 87.1; P<0.001) for nirsevimab. Hospitalization for RSV-associated lower respiratory tract infection occurred in 6 infants (0.6%) in the nirsevimab group and in 8 infants (1.6%) in the placebo group (efficacy, 62.1%; 95% CI, −8.6 to 86.8; P=0.07). Among infants with data available to day 361, antidrug antibodies after baseline were detected in 58 of 951 (6.1%) in the nirsevimab group and in 5 of 473 (1.1%) in the placebo group. Serious adverse events were reported in 67 of 987 infants (6.8%) who received nirsevimab and in 36 of 491 infants (7.3%) who received placebo. A single injection of nirsevimab administered before the RSV season protected healthy late-preterm and term infants from medically attended RSV-associated lower respiratory tract infection. (Funded by MedImmune/AstraZeneca and Sanofi; MELODY ClinicalTrials.gov number, NCT03979313.)

27 April 2020 in Clinical Infectious Diseases
Verified
Journal Article
Open access
PDF file
ABAdarsh Bhimraj
Adarsh Bhimraj
RMRebecca L. Morgan
Rebecca L. Morgan
ASAmy Hirsch Shumaker
Amy Hirsch Shumaker
VLValery Lavergne
Valery Lavergne
LBLindsey Baden
Lindsey Baden
YFYngve Falck-Ytter
Yngve Falck-Ytter
Background: There are many pharmacologic therapies that are being used or considered for treatment of coronavirus disease 2019 (COVID-19). There is a need for frequently updated practice guidelines on their use, based on critical evaluation of rapidly emerging literature. The objective was to develop evidence-based rapid guidelines intended to support patients, clinicians, and other healthcare professionals in their decisions about treatment and management of patients with COVID-19. Methods: The Infectious Diseases Society of America (IDSA) formed a multidisciplinary guideline panel of infectious disease clinicians, pharmacists, and methodologists with varied areas of expertise. Process followed a rapid recommendation checklist. The panel prioritized questions and outcomes. Then a systematic review of the peer-reviewed and gray literature was conducted. The Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach was used to assess the certainty of evidence and make recommendations. Results: The IDSA guideline panel agreed on 7 treatment recommendations and provided narrative summaries of other treatments undergoing evaluations. Conclusions: The panel expressed the overarching goal that patients be recruited into ongoing trials, which would provide much-needed evidence on the efficacy and safety of various therapies for COVID-19, given that we could not make a determination whether the benefits outweigh harms for most treatments.

30 July 2020 in JAMA Pediatrics
Verified
Journal Article
Open access
PDF file
THTaylor Heald-Sargent
Taylor Heald-Sargent
WMWilliam J. Muller
William J. Muller
XZXiaotian Zheng
Xiaotian Zheng
JRJason Rippe
Jason Rippe
APAmi B. Patel
Ami B. Patel
LKLarry K. Kociolek
Larry K. Kociolek
This cohort study investigates age-related differences in nasopharyngeal severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) levels in patients with mi

20 April 2023 in New England Journal of Medicine
Verified
Journal Article
Closed access
WMWilliam J. Muller
William J. Muller
SMShabir Ahmed Madhi
Shabir Ahmed Madhi
BNBeatriz Seoane Nuñez
Beatriz Seoane Nuñez
MCManuel Baca Cots
Manuel Baca Cots
MBMiroslava Bosheva
Miroslava Bosheva
TVTonya Villafana
Tonya Villafana

19 October 2022 in New England Journal of Medicine
Verified
Journal Article
Closed access
PDF file
EAEvan Anderson
Evan Anderson
CCC. Buddy Creech
C. Buddy Creech
VBVladimir Berthaud
Vladimir Berthaud
APArin Piramzadian
Arin Piramzadian
KJKimball A. Johnson
Kimball A. Johnson
SGSabine Schnyder Ghamloush
Sabine Schnyder Ghamloush
The safety, reactogenicity, immunogenicity, and efficacy of the mRNA-1273 coronavirus disease 2019 (Covid-19) vaccine in young children are unknown. Part 1 of this ongoing phase 2–3 trial was open label for dose selection; part 2 was an observer-blinded, placebo-controlled evaluation of the selected dose. In part 2, we randomly assigned young children (6 months to 5 years of age) in a 3:1 ratio to receive two 25-μg injections of mRNA-1273 or placebo, administered 28 days apart. The primary objectives were to evaluate the safety and reactogenicity of the vaccine and to determine whether the immune response in these children was noninferior to that in young adults (18 to 25 years of age) in a related phase 3 trial. Secondary objectives were to determine the incidences of Covid-19 and severe acute respiratory syndrome coronavirus 2 infection after administration of mRNA-1273 or placebo. On the basis of safety and immunogenicity results in part 1 of the trial, the 25-μg dose was evaluated in part 2. In part 2, 3040 children 2 to 5 years of age and 1762 children 6 to 23 months of age were randomly assigned to receive two 25-μg injections of mRNA-1273; 1008 children 2 to 5 years of age and 593 children 6 to 23 months of age were randomly assigned to receive placebo. The median duration of follow-up after the second injection was 71 days in the 2-to-5-year-old cohort and 68 days in the 6-to-23-month-old cohort. Adverse events were mainly low-grade and transient, and no new safety concerns were identified. At day 57, neutralizing antibody geometric mean concentrations were 1410 (95% confidence interval [CI], 1272 to 1563) among 2-to-5-year-olds and 1781 (95% CI, 1616 to 1962) among 6-to-23-month-olds, as compared with 1391 (95% CI, 1263 to 1531) among young adults, who had received 100-μg injections of mRNA-1273, findings that met the noninferiority criteria for immune responses for both age cohorts. The estimated vaccine efficacy against Covid-19 was 36.8% (95% CI, 12.5 to 54.0) among 2-to-5-year-olds and 50.6% (95% CI, 21.4 to 68.6) among 6-to-23-month-olds, at a time when B.1.1.529 (omicron) was the predominant circulating variant. Two 25-μg doses of the mRNA-1273 vaccine were found to be safe in children 6 months to 5 years of age and elicited immune responses that were noninferior to those in young adults. (Funded by the Biomedical Advanced Research and Development Authority and National Institute of Allergy and Infectious Diseases; KidCOVE ClinicalTrials.gov number, NCT04796896.)

12 July 2019 in Open Forum Infectious Diseases
Verified
Journal Article
Open access
PDF file
JRJenna Rossoff
Jenna Rossoff
SCSonali Chaudhury
Sonali Chaudhury
MSMaulin Soneji
Maulin Soneji
SPSameer J Patel
Sameer J Patel
SKSoyang Kwon
Soyang Kwon
WMWilliam J Muller
William J Muller
Pediatric patients frequently present with illnesses strongly suggesting infection, but without a clearly identified etiology. Our center has recently added a commercially available plasma metagenomic sequencing assay to its available diagnostic testing. Our experience with the first 100 tests suggests that this technology has good clinical performance with >90% sensitivity.